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Summary
Purpose: This phase II multi-institutional trial was designed
to assess response and toxicity of 2-chlorodeoxyadenosine
(2-CDA) in patients with previously untreated follicular lym-
phoma. The clinical significance of detecting cells carrying
the t(14;18) translocation (bcl-2/JH rearrangement) in pe-
ripheral blood and bone marrow by polymerase chain reac-
tion (PCR) before, during and after treatment was also exam-
ined.
Patients and methods: Between May 1993 and October
1995, 37 patients were accrued: male/female: 15/22, median
age 51 years (range: 20-78), stage TH/TV: 9/28. Patients re-
ceived a total 2-CDA dose of 0.7 mg/kg as continuous s.c. or
i.v. infusions over 7 days, every 28 days for a maximum of 5
cycles. A total of 165 cycles were administered. In 25 pa-
tients, blood and bone marrow before, during and after treat-
ment were available for PCR analysis of the bcl-2/JH re-
arrangements.
Results: All 37 patients were evaluable for response and
toxicity. The overall response rate was 84% (95% confidence
interval, 68%-94%) with 14% CR (n - 5) and 70% PR (n -
26) and a median time to treatment failure of 15.7 months.
bcl-2/JH rearrangement in peripheral blood and/or bone
marrow was found in 10/25 of patients (40%) before treat-
ment and 5 of these became repeatedly negative after 2-CDA
therapy. There was no apparent association between bcl-2/
JH result and response. In 11 patients, 2-CDA was stopped
because of progressive disease (n — 4), myelotoxicity (grade
2-3, n = 4), and other causes (n — 3, pulmonary embolism,
metabolic disorder, and patient's decision). Four patients
(11%) suffered from infections (grade 2-3). In 6 patients,
persistent thrombocytopenia of 7.5 months (range: 3-21)
occurred after completion of the 5 cycles.
Conclusion: 2-CDA is active in untreated follicular lym-
phomas, but time to treatment failure suggests no advantage
compared with standard treatment and toxicity on haemato-
poietic stem cells appears to be more pronounced. Molecular
remission is induced in a considerable proportion of patients
with disappearance of the bcl-2/JH rearrangement, and its
possible significance as a predictive factor for quality of re-
sponse and relapse warrants further study.
Key words: bcl-2 rearrangement, 2-chlorodeoxyadenosine,
cladribine, follicular lymphoma, t(14;18) chromosomal
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Introduction
Follicular lymphomas represent the most common sub-
type of malignant lymphomas. The cornerstone for
diagnosis is, amongst others, the presence of a follicular
growth pattern and, at the molecular level, the iden-
tification of a chromosomal translocation t(14;18)
(q32;q21) that leads to the juxtaposition of the bcl-2
oncogene on chromosome 18q21 adjacent to the
immunoglobulin heavy-chain locus on chromosome
14q32. The clinical course of follicular lymphomas is
comparable with other low grade lymphomas; the
median survival ranges from 5-10 years and remissions
can be induced either by single drug treatment or com-
bination chemotherapy. In the majority of patients with
advanced disease, however, none of the current treat-
ment modalities result in prolonged relapse free sur-
vival and most patients ultimately die of disease [1-5].
New treatment strategies must therefore be developed.
Intensive chemotherapy followed by autologous bone
marrow transplantation is an interesting approach,
which may prolong relapse free survival. However, effi-
cacy in terms of cure has not yet been shown [6].
Assessment of residual disease at the molecular level
(t(14;18) chromosomal translocation) is currently in
experimental phase and might be of value in the predic-
tion of relapses and, perhaps, it will help to improve the
timing of treatment [7-10].
In the last decade, various new drugs, mainly purine
analogues, have shown activity in a great proportion of
patients with low grade lymphomas. 2-Chlorodeoxy-
adenosine (2-CDA) is one of these purine analogues
[11-13], which is highly active in pretreated low-inter-
mediate grade non-Hodgkin's lymphoma (NHL) [14-
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17]. In two studies follicular lymphoma appeared to be
more responsive to 2-CDA with 50% responses com-
pared to 30% in patients with diffuse growth pattern
[15,17].
In 1993, the Swiss Group for Clinical Cancer Re-
search (SAKK) initiated this phase II trial of 2-CDA in
non-pretreated patients with advanced follicular NHL
to study activity, toxicity, remission duration and sur-
vival. As a secondary objective, the prognostic value of
residual disease in bone marrow and peripheral blood
by the PCR examination of mononuclear cells carrying
the (14;18) translocation (bcl-2/JH rearrangement)
was assessed.
Patients and methods
Study design
This study was a multicentre, phase II trial initiated by the SAKK in
May 1993. Ten centres participated in this trial (see Appendix). The
protocol was approved by the local ethics committees of each par-
ticipating centre. The study was performed in keeping with good
clinical practice and informed consent was given by all patients. The
trial was closed for accrual in October 1995.
Eligibility criteria
Patients were required to have newly diagnosed stage IH-IV follicu-
lar small, mixed or large cell NHL (IWF B-D [International Working
Formulation for Clinical Usage| or follicle centre cell lymphoma,
follicular grade I-III according to the REAL classification |revised
European and American Lymphoma Classification]). Histological
diagnosis was performed immediately before enrollment All diag-
noses were confirmed by central pathology review (K.B.). Age limits
were originally set between 18 and 80 years, but due to 2-CDA
induced toxicity (pneumonia, grade 3, and fatal pulmonary embo-
lism) the upper age limit was reduced to 72 years after enrollment of
18 patients. Patients were not included if they had a life expectancy
of less than 3 months, if they had had prior malignancy other than
non-melanomatous skin cancer or adequately treated stage I in situ
cervical cancer, if they had another life threatening disease (kidney
dysfunction, cardiac failure etc.) or if they had peripheral blood
cytopenia (leucocyte count <3.0 x 109/l, neutrophil count <1.0 x
109/l and thrombocyte count < 100 x 1071) unless this was clearly
related to bone marrow infiltration with NHL.
Pretreatment investigations
The extent of disease was determined by standardised staging
evaluation, which included CT scanning of the chest, abdomen and
pelvis, and bone marrow aspiration and trephine biopsy. In the case
of gastrointestinal symptomatology or involvement of Waldeyer's
ring, a gastroscopy and head and neck evaluation was performed.
Kidney function (creatinine and urine analysis), liver enzymes, and
LDH were measured and lymphocyte immunophenotyping (CD4,
CD8), protein electrophoresis and electrocardiogram performed
before 2-CDA therapy was initiated.
Drug therapy
Patients were treated with 2-chlorodeoxyadenosine (cladribine)
(Lipomed, Basel, Switzerland) at a dose of 0.1 mg/kg/day diluted in
0.9% saline solution as continuous i.v. or s.c. infusions over 7 days.
For subcutaneous administration, 2-CDA solution was injected
using a Disetronic Infusor* pump system, kindly provided by Dise-
tronic AG (Burgdorf, Switzerland). 2-CDA cycles were repeated at
4 week intervals for a maximum of 5 cycles. Treatment was delayed
if the neutrophil count was less than 1.0 x 1071 and/or the platelet
count less than 100 x 1071 (until recovery), unless the cause was
clearly due to infiltration of the bone marrow by the NHL. No anti-
microbial prophylaxis was given, and no concomitant therapy such
as antiemetics or steroids were administered. Treatment was discon-
tinued in case of disease progression after 3 cycles.
Response criteria
All initial sites of disease were reassessed after 3 and 5 treatment
cycles. A complete remission (CR) was defined as absence of detect-
able disease on two measurements separated by an interval of at
least 4 weeks. In particular, all lymph nodes had to reveal normal
size as judged by physical examination and CT scanning of the chest,
abdomen, and pelvis, and the bone marrow biopsy had to show less
than 20% lymphocytes and no evidence of abnormal lymphoid infil-
tration. A partial remission (PR) was defined as a reduction in all
involved areas of disease by at least 50%. Any response less than
that sufficient to qualify as a PR was no change (NC). Progressive
disease was defined as a >25% increase in measurable disease or
the occurrence of new lesions.
Toxicity criteria
Toxicity was evaluated according to World Health Organization
(WHO) criteria [18]. Physical examination and full blood count in-
cluding differential were done weekly. Serial immunophenotyping of
peripheral blood lymphocytes was performed before each treatment
cycle and at regular intervals after completion of therapy.
Statistical analyses
All patients were evaluated for toxicity, response and survival. Time
to treatment failure was calculated from date of enrollment to either
disease progression/relapse, discontinuation of treatment for toxic-
ity or death from any causes. Event-free survival was calculated
from the date of enrollment to disease progression, relapse, or death
and overall survival from the date of enrollment to death for any
cause. Response duration was calculated from the date of response
until relapse, progression or death. The cutoff for all the above cal-
culations was March 15, 1996. Survival curves were compared using
the log-rank test. Contingency tables were analysed by Fisher's exact
test, while continuous variables were analysed by Wilcoxon signed
rank test (one sample) or Wilcoxon rank sums test (two samples).
The level of significance was P - 0.05.
Assessment of the bcl-2/JH rearrangement
Whole blood (5 ml) and bone marrow (2 ml) samples, stored at
-20 *C, were treated with lysis buffer (0.32 M sucrose, 10 mM Tris-
HC1 pH 7.5, 5 mM MgCl2, 1% Triton X-100) to remove red cells.
The cell pellet obtained by centrifugation (15 min at 3000 rpm) was
then resuspended in 100 mM NaCl, 25 mM EDTA, 0.5% SDS and
200 M-g/ml proteinase K (Sigma, St. Louis, USA) and incubated
overnight at 37 *C. DNA was extracted by phenol-chloroform and
precipitated in ethanol. Small pellets were resuspended in a diges-
tion buffer (1 x PCR buffer, 0.5% Tween 20 and 200 ug/ml pro-
teinase K for 100 ul) and incubated at 56 *C for 90 min and then at
94 'C for 20 min to inactivate enzymatic activity. DNA presence was
tested with a PCR assay using PCO4 (5'CAACTTCATCCAC-
GTTCACC-3) and GH20 (5-GAAGAGCCAAGGACAGGTAC-
31) primers (Perkin Elmer, Norwalk, USA) which amplifies a 268 bp
segment of the f$ globin gene. 1.5 \ig of phenol-chloroform extracted
DNA or 5 ul of digestion buffer extracted DNA were analysed.
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Nested PCR reactions were performed in 50 nl volumes including
1 x PCR buffer (50 mM KC1, 10 mM Tris-HCl pH 8.4, 2.5 mM
MgCl2)> 200 nM of each deoxynucleotide (Pharmacia, Uppsala,
Sweden), 25 pmol of each primer and 1.25 U Taq polymerase
(GIBCO, Gaithesburg, USA). The first round of the nested PCR
amplification was performed for 30 cycles with the outer primers
5'ACCTGAGGAGACGGTGACC-3' for the JH region and 5'CA-
GCCTTGAAACATTGATGG-3' for MBR (Pharmacia Biotech,
Rosendaal, the Netherlands). Each cycle included 45 sec of
denaturation at 95 'C, 1 min of annealing at 60 *C and 2 min of
extension at 72 "C. A touch-down PCR technique was used starting
from annealing temperature of 60 "C then decreased by 1 "C every
two of the first eight cycles. Of first round DNA product, 5 ul was re-
amplified for 30 cycles with inner primers 5'CAGGGTTCCTTG-
GCCCCAG-3' for the JH region and 5'-AGTTGCTTTACGTGG-
CCTGT-3' for MBR (Pharmacia Biotech). Each cycle included 45
sec of denaturation at 94 "C, 1 min of annealing at 57 "C and 1 min
of extension at 72 "C. DNA amplification always started with 10 min
of initial denaturation at 95 "C and finished with 10 min of final
extension at 72 "C. Patient samples were always analysed together
with human B-cell lymphoma cell line DOHH2 (kindly provided by
Dr. F. E. Cotter, London, UK) as a positive control and the reaction
mixture with no DNA as negative reagent control. Of the nested
PCR product, 10 ul were loaded in 2% agarose electrophoresis gel
containing ethidium bromide and visualized under ultraviolet light.
Results
Study population
Thirty-seven patients with previously untreated follicu-
lar NHL stage ffl-IV were enrolled between May 1993
and October 1995. In 36 patients the diagnosis was
established by lymph node biopsy and in one patient by
bone marrow biopsy alone. In all cases results of pa-
thology review was in accordance with the diagnosis
made by the local pathologist. There were 16 patients
with follicular small (IWF B, REAL, follicle centre cell,
follicular grade I), IS patients with follicular mixed
(IWF C, REAL, follicular grade n) and 3 patients with
follicular large cell lymphomas (IWF D, REAL, follicu-
lar grade HI). One hundred and sixty-five cycles of
2-CDA were administered to 37 patients. The median
number of cycles was 5 (range, 2 to 5 cycles), with 26
patients receiving the full 5 cycles of 2-CDA according
to protocol. Treatment was stopped prematurely in 11
patients due to death [progressive disease (n — 2), pul-
monary embolism (n — 1) and metabolic disorder (dia-
betes mellitus, n —1)], progressive disease (n — 2),
toxicity [persistent thrombocytopenia (« — 3) or neu-
tropenia (n — 1)] and patient's decision (n — 1). The
median actual dose-intensity for all patients was 0.17
mg/kg/week (range 013-0.21 mg/kg/week) and did
not differ between responders and non-responders. Pa-
tient characteristics are listed in Table 1.
Response to therapy
The overall response rate in 37 patients was 84% (95%
confidence interval (CI), 68% to 94%), with a CR rate
of 14% (95% CI, 5%-29%) and a PR rate of 70%
(95% CI, 53%-84%). All 31 responders had reached at
least a PR after three cycles of 2-CDA. Table 2 sum-
marises patient response by histological subtype. Seven
of 8 complete remissions occurred in follicular mixed
lymphomas (IWF C, REAL, follicle centre cell, follicu-
lar grade II) (P •= 0.02). On the cutoff date 71% of the
responders were still under remission. The 75% quan-
tile response duration was 15.2 months.
After 5 cycles of 2-CDA, the patients were observed
without receiving further therapy until relapse or pro-
gression. The median time to treatment failure was 15.7
months (Figure 1). The median follow-up time (from
enrollment) of all patients was 20.3 months. The one
year event-free and overall survival rates were 73%
(27/37) and 89% (33/37), respectively.
We tested several parameters known to be prognos-
tic factors associated with event-free survival [1, 19].
Although the median event-free survival has not been
Table 1. Patient characteristics (n - 37).
Characteristic No.
Age, years
Median
Range
Gender
Male
Female
Histology
IWF B, REAL, follicle centre cell, follicular grade I
IWF C, REAL, follicle centre cell, follicular grade U
IWF D, REAL, follicle centre cell, follicular grade III
Ann Arbor stage
III
IV
Number of nodular sites
1-2
3-4
>5
Bone marrow involvement
Present
Absent
Number of patients with
Splenomegaly
Hepatomegaly
Criteria for high tumor burden
Tumor mass > 7 cm
B-symptoms
Liver function tests
AS AT (<1.5 x upper normal limit)
ASAT (> 1.5 x upper normal limit)
Serum lactate dehydrogenase (LDH) level
Normal - <1.5 x upper normal limit
>1.5 x upper normal limit
51
20-78
15
22
16
18
3
9
28
5
15
17
26
11
19
8
14
12
35
2
32
5
Table 2. Response rate by histological subtype.
IWF
B
C
D
Descrip-
tion:
follicular
Small cell
Mixed cell
Large cell
REAL1
1
II
III
N pa-
tients
16
18
3
Response
Over-
all
14
15
2
CR
1
7
0
PR
13
8
2
Response dura-
tion (months)
median (range)
13.9+(3.7-21.3)
16.7+ (1.1-33.4)
19.5+(17.5-21.9)
REAL, follicle centre cell, follicular grade I—III-
reached, it was reduced in male patients (P = 0.05), in
patients with worse performance status (PS 0 versus PS
1-2, P= 0.003), in patients with spleno- and/or hepa-
tomegaly (P = 0.03), and if LDH was increased at study
entry (<1.5 x UNL versus >1.5 x UNL, P- 0.0002).
Age, presence of B-symptoms, Ann Arbor stage (HI
versus TV), and bone marrow involvement had no prog-
nostic value in our series, probably due to the low
patient number and relatively short observation time.
The 2-CDA activity on lymphocytes as well as CD4
and CD8 positive cells was assessed regularly during
and after 2-CDA therapy. The median lymphocyte
count including CD4 and CD8 cells decreased
throughout the period of treatment attaining the lowest
value (total lymphocyte count: 0.4 x 109/l; CD4: 0.11 x
109/l; CD8: 0.08 x 109/l) at its completion. The total
lymphocyte count did not recover to pretreatment
values until 12 months after the completion of the
2-CDA therapy (P < 0.012) (Figure 2).
Bcl-2/JH rearrangement
One of the study objectives was to define whether the
presence of mononuclear cells carrying the t(14;18)
translocation in PB and BM would have any clinical
significance in predicting relapse. Seventy-seven PB
and 70 BM samples from 25 patients were available for
investigation. Bcl-2/JH rearrangement was found in
10/25 of patients (40%) at study entry and 5 became
negative after 2-CDA therapy. No progression has been
seen in these 5 patients. Conversely, one of 3 patients
remaining positive for bcl-2 rearrangement relapsed
after 8 months. The results are detailed in Table 3.
Besides, among the 25 patients, there were only 3 non-
responders, whose bcl-2/JH results were negative.
Toxicity
Non-hematologic toxicity was mild. In particular, nau-
sea or vomiting did not occur and no patient had muco-
sitis, neurologic symptoms, or alopecia. No drug relat-
ed renal or hepatic toxicity was encountered. In 29
patients (126 cycles), 2-CDA was administered sub-
cutaneously to out-patients using a Disetronic* pump
system. This system was well tolerated except for mod-
erate exanthema and induration at the injection site in
69 of 126 cycles.
Grade 3 or 4 neutropenia was experienced by 8 of
37 patients, in 12 of 35 cycles. Recovery to baseline
values was usually seen by day 28. In one patient ther-
apy had to be delayed by 4 days because of a low neu-
trophil count. Grade 3 and 4 thrombocytopenia was
seen in 4 of 37 patients (4 of 15 cycles). No haemor-
Figure 1. Time to treatment failure (n - 37).
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Figure 2. Median lymphocyte counts (total, CD4 and CD8 positive
cells).
Table 3. Bcl-2/JH rearrangement in mononuclear cell fraction of
peripheral blood (PB) and bone marrow (BM) assessed by PCR
amplification (x — no DNA available for bcl-2/JH rearrangement
analysis).
UPN
19
20
21
28
32
35
36
39
PB/
BM
Before
ther-
apy
After 3
cycles
After 5
cycles
At
relapse
PB
BM
PB
BM
PB
BM
PB
BM
PB
BM
PB
BM
PB
BM
PB
BM
PB
BM
PB
BM
Histo- Remis-
logical sion
BM in- duration
volve- (months)
mem
33.4+
25.8+
1.6
18.2+
17.4+
13.1+
10.3+
11.8+
9.1+
8.3
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rhages occurred, and no platelet support was necessary.
Median values of neutrophils and platelets during and
after completion 2-CDA therapy are shown in Figure
3.
Although there was no evidence of cumulative
myelosuppression on day 14 for neutrophils (neutro-
penia of WHO grade > 3 in 4/37 patients after cycle 1,
in 2/35 patients after cycle 3 and in 0/26 patients after
cycle 5), persistent thrombocytopenias (median 73 x
109/l, range 15-93) occurred in 9 patients. In six pa-
tients, platelet counts still decreased one to six months
after completion of the 2-CDA therapy. In a further 3
patients 2-CDA had to be discontinued after the 3rd
(n = 1), or the 4th (n = 2) cycle of 2-CDA. This myelo-
toxicity showed no recovery after 7.5 months (median,
range 3-21 months). Age, gender, stage, performance
status and presence of B-symptoms, LDH and ASAT
levels, splenomegaly, hepatomegaly, lymphocyte and
neutrophil counts before and during treatment, re-
sponse, histological subtype, number of nodular sites,
bone marrow involvement as well as tumor burden
were not associated with a higher risk to acquire de-
layed persistent thrombocytopenia. In one patient,
thrombocytopenia was associated with neutropenia
which lasted for 21 months. Further investigations in-
cluding cytogenetic analysis and stem cell cultures led
to the diagnosis of a myelodysplastic syndrome with
monosomy of chromosome 7 and trisomy of chromo-
some 8.
Infectious complications were rare. Nine patients
(b)
_ 200
—
50
0
2-CDA cycle
10 1 5
Months
Figure 3. Median neutrophil (a) and thrombocyte (b) counts are
shown during and after therapy.
(11 cycles) experienced grade 1-2 infections including
bacterial urinary infection (n — 3), herpes genitalis
(n = 2), herpes zoster (n - 1), viral pharyngitis (n - 4),
and paronychia of the finger (n - 1). One patient suf-
fered from pneumonia (grade 3). No patient developed
a significant infection between cessation of 2-CDA
treatment after achieving a response until cut off
(March 15, 1996) or resumption of chemotherapy be-
cause of relapse.
Discussion
The activity of 2-CDA in low grade lymphoma has
been studied by several investigators. Overall remission
rates are in the range of 22%-70% in pretreated and
60%-100% in previously untreated patients with low
grade lymphomas [12, 14-17, 20-26]. Almost all stud-
ies assembled very heterogeneous groups of patients
with different lymphoma types. Additionally, there is so
far only little information regarding time to treatment
failure and event-free survival, and experience with this
drug in non-pretreated NHL patients is still limited.
In the present study we examined a homogenous
group of previously untreated patients with advanced
foUicular lymphoma. All patients required therapy due
to high tumour burden and/or bone marrow involve-
ment. The results show 2-CDA to have significant
activity as a single agent with an overall response rate
of 84% (14% CR). Complete remissions appeared to
occur more frequently in patients with mixed cell fol-
licular lymphomas (IWF C, REAL, follicle centre cell,
follicular grade II) (P = 0.02). Our response rate is in
agreement with the recent study reported by Saven et
al. [27], in which 10 patients with previously untreated
follicular NHL are described (3 patients with CR and 5
with PR). In our study, all responders had reached a PR
after three cycles of 2-CDA, and it appears therefore
that continuation of the drug in patients with no re-
sponse after 3 cycles is not indicated. In advanced fol-
licular lymphomas, time to treatment failure, event-free
and overall survival are the most important end points.
The median time to treatment failure for our 37 assess-
able patients in the present study was 15.7 months
which is very similar to that obtained after other ther-
apies. Median event-free and overall survival have not
yet been reached.
Very recently, a trial assessing another purine ana-
logue, fludarabine phosphate, has been reported in pre-
viously untreated patients with foUicular NHL [28].
The overall response of 65% (however, with a greater
rate of CRs of 37%) and the median time to treatment
failure of 9 months were similar to our results. When
comparing these data to previously reported studies
with cyclophosphamide or vinca alkaloids, 2-CDA and
fludarabine phosphate appear, however, to possess
similar activity [5].
The t(14;18)(q32;q21) chromosomal translocation
is a consistent feature of follicular lymphomas and pre-
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sents an opportunity for the molecular monitoring of
subclinical disease. This translocation juxtaposes the
bcl-2 proto-oncogene on chromosome 18q21 with
the joining region (JH) of the immunoglobulin heavy
chain on chromosome 14q32 and results in overexpres-
sion of a functionally normal bcl-2 protein, which in
turn leads to a reduction of apoptosis and a growth
advantage for the neoplastic clone. The majority of
breakpoints on chromosome 18 are clustered in two
areas; the major breakpoint region (MBR) in approxi-
mately 60% and the minor cluster region (mcr) in 10%-
20% of cases [29]. The PCR using consensus JH
primer and primers specific to one or more bcl-2
gene breakpoints regions, is a sensitive and repro-
ducible assay for detecting the bcl-2/JH rearrangement
[30]. This rearrangement was detected in the BM and/
or PB mononuclear cells from 10 of 25 patients (40%).
This relatively low frequency may be explained by the
fact that PCR analyses generally underestimate the
rearrangement frequency [31]. In a survey of follicular
lymphoma, in which a translocation frequency of 76%
was determined by cytogenetics, PCR analyses led to a
detection of only 46% when examining the major
breakpoint region [31]. This is presumably due to
breakpoints falling outside the range of primers used.
Nevertheless, we were interested to know whether a
conversion from positive to negative correlated with
clinical response and long remission duration. In our
study, 5 patients showed this pattern, but another 3
patients showed PCR positivity which remained un-
changed during treatment. As shown in Table 3, there is
so far no apparent association between this result and
outcome. These data are in agreement with previous
studies showing the absence of predictive value when
the bcl-2/JH rearrangement was measured in blood or
bone marrow mononuclear cells [32, 33]. Indeed, no
study has yet shown that a clearance of bcl-2 rear-
ranged cells from BM and PB results in a better sur-
vival. Further investigations are therefore needed to
definitely evaluate a possible significance of (14;18)
translocation assessments at regular intervals.
Non-hematological toxicity of 2-CDA was moder-
ate. The infection rate was low and there were no other
significant adverse effects. In particular, neurotoxicity
frequently observed when using purine analogues was
not seen and no alopecia or severe nausea were en-
countered. Infections have been reported to occur fre-
quently after 2-CDA therapy in pretreated patients [15,
17, 34], but in this study, infections (grade 2-3) were
seen in only 4 patients (11%).
The most significant toxicity was myelotoxicity. Me-
dian platelet, neutrophil and total lymphocyte counts
had not recovered to baseline value 13 months after the
cessation of 2-CDA. In particular, a persistent and
delayed thrombocytopenia occurred in 9/37 (24%) pa-
tients, and in one case a myelodysplastic state was
diagnosed. Severe treatment-related thrombocytopenia
has also been reported by Carson et al. [35] using a
larger dose of 2-CDA (0.1-1 mg/kg over 14 days) in
pretreated patients and, in a recent study of non-pre-
treated chronic lymphocytic leukaemia patients report-
ed by Saven et al. [36], grade 3-4 thrombocytopenia
occurred in 23%-40% of cases. The mechanism by
which this important adverse effect is induced is not
clear and in our study, we found no factor associated
with a greater risk of persistent thrombocytopenia.
In conclusion, these results show that 2-CDA is
effective in previously untreated follicular lymphomas,
although in terms of response rate and remission dura-
tion, the drug does not appear to be more active than
standard therapy. The persistent thrombocytopenia, in
some patients is of concern and further studies, per-
haps with a reduced 2-CDA dose (0.5 mg/kg/cycle),
are needed before a clear role for 2-CDA in the treat-
ment of low grade lymphomas can be established.
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